OpenAlex
PricingAboutJobs
Log inGet started
Work

Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B

HTML

Year: 2019
Type: conference-abstract
Source: Blood
DOI: 10.1182/blood-2019-122535
Authors: Wolfgang Miesbach, Karina Meijer, Michiel Coppens, Peter Kampmann, Dr. Klamroth, Roger Schutgens, Giancarlo Castaman, Erhard Seifried, Joachim Schwaeble, Halvard Bönig, Eileen K Sawyer, Frank W.G. Leebeek
Institutions: University Hospital Frankfurt, University Medical Center Groningen, Amsterdam UMC Location University of Amsterdam, Rigshospitalet, Vivantes Klinikum, University Medical Center Utrecht, Azienda Ospedaliero-Universitaria Careggi, German Red Cross, Erasmus MC, UniQure (Netherlands)
Language: English

Topic: Hemophilia Treatment and Research
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: hemophilia B, gene therapy, factor IX, long-term efficacy, annualized bleeding rate, prophylaxis discontinuation, factor IX activity, immunological biomarkers, inflammatory markers, treatment-related adverse events, liver-directed gene transfer, durable response
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2988604109
Cites:
Cited by: 27
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security